UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 91.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,292 shares of the medical instruments supplier's stock after acquiring an additional 9,189 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.36% of Mesa Laboratories worth $2,544,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of MLAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Mesa Laboratories by 3.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,925 shares of the medical instruments supplier's stock valued at $386,000 after acquiring an additional 98 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Mesa Laboratories by 3.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 3,394 shares of the medical instruments supplier's stock valued at $448,000 after buying an additional 100 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Mesa Laboratories by 2.6% during the 4th quarter. Alliancebernstein L.P. now owns 5,584 shares of the medical instruments supplier's stock valued at $736,000 after purchasing an additional 141 shares in the last quarter. Amundi grew its position in shares of Mesa Laboratories by 81.6% during the 4th quarter. Amundi now owns 661 shares of the medical instruments supplier's stock valued at $91,000 after purchasing an additional 297 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Mesa Laboratories by 12.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,469 shares of the medical instruments supplier's stock valued at $458,000 after purchasing an additional 390 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MLAB. Wall Street Zen lowered shares of Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 30th. Wells Fargo & Company cut their target price on shares of Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating for the company in a research report on Friday, May 30th.

Mesa Laboratories Price Performance

NASDAQ:MLAB traded up $1.49 during midday trading on Tuesday, hitting $104.35. The company had a trading volume of 302,711 shares, compared to its average volume of 43,552. Mesa Laboratories, Inc. has a 52-week low of $83.68 and a 52-week high of $155.12. The stock's fifty day moving average price is $112.84 and its 200-day moving average price is $126.12. The company has a market capitalization of $569.23 million, a PE ratio of -2.26 and a beta of 0.88. The company has a quick ratio of 0.53, a current ratio of 0.71 and a debt-to-equity ratio of 0.61.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Friday, May 30th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.61%. The ex-dividend date of this dividend is Friday, May 30th. Mesa Laboratories's dividend payout ratio is presently -172.97%.

Insiders Place Their Bets

In other Mesa Laboratories news, CEO Gary M. Owens sold 21,000 shares of the business's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the sale, the chief executive officer now directly owns 43,337 shares of the company's stock, valued at $5,369,887.67. The trade was a 32.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.40% of the stock is currently owned by insiders.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.